ReviewMolecular and clinical oncology2014
Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.
Review in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Prognostic and immune implications of a novel ferroptosis-related ten-gene signature in lung adenocarcinoma.Annals of translational medicine · 2021Article
- Functional inhibition of heat shock protein 70 by VER-155008 suppresses pleural mesothelioma cell proliferation via an autophagy mechanism.Thoracic cancer · 2021Article
- Autophagy-Related Three-Gene Prognostic Signature for Predicting Survival in Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- Chloroquine increases the anti-cancer activity of epirubicin in A549 lung cancer cells.Oncology letters · 2020Article
- Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling.Journal of Cancer · 2020Article
- Prognostic implications of autophagy-associated gene signatures in non-small cell lung cancer.Aging · 2019Article
- Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.Oncology research · 2018Article
- Functions of autophagy in the tumor microenvironment and cancer metastasis.The FEBS journal · 2018Review
- New Chimeric Antigen Receptor Design for Solid Tumors.Frontiers in immunology · 2017Review
- Article
- Autophagy inhibition upregulates CD4Molecular oncology · 2016Article
- [Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Review
- Mutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma.Journal of thoracic disease · 2016Article
- Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia.Autophagy · 2016Article
- Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines.International journal of oncology · 2016Article
- EGFR-Signaling and Autophagy: How they Fit in the Cancer Landscape.Journal of adenocarcinoma · 2016Article
- ATG7 promotes the tumorigenesis of lung cancer but might be dispensable for prognosis predication: a clinicopathologic study.OncoTargets and therapy · 2016Article
- Novel Mechanisms for the Antifibrotic Action of Nintedanib.American journal of respiratory cell and molecular biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. However, the majority of tumors develop acquired resistance to EGFR-TKIs after a median of 10-16 months, which limits the clinical efficacy of these drugs. Autophagy, an important homeostatic cellular recycling mechanism, has emerged as a potential target for the acquired resistance phenotype. Recently, several studies demonstrated that autophagy may be induced in a dose-dependent manner by treatment of multiple cancer cell lines with EGFR-TKIs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.